Chinese Biotech Start-Up Juventas Gets $14M In Series A+ Round

Login to View

Chinese biotechnology start-up Juventas announced on Tuesday that it has raised RMB100 million (US$14.51 million) in a series A+ round of financing led by Nasdaq-listed pharmaceutical firm CASI Pharmaceuticals.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now


Already have an account or paid subscription? Log in


RELATED NEWS